



## AMENDMENTS TO THE CLAIMS:

1. (Currently Amended) A method for treating a ~~CNS disorder associated with impaired prefrontal cortical function~~ bipolar disorder or a working memory deficit in a subject comprising administering to said subject in need thereof an effective amount of a pharmaceutical composition comprising a ~~compound~~ chelerythrine or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof, ~~according to the structure:~~



(I)

or



(II)

wherein:

$R^1$  and  $R^2$  are independently selected from H,  $C_1$ - $C_3$ alkyl, F, Cl, Br, I, OH,  $O(C_1$ - $C_6$ alkyl),  $O-C(=O)-(C_1$ - $C_6$ alkyl) or  $C(=O)-O-(C_1$ - $C_6$ alkyl);

$R^3$  is H or a  $C_1$ - $C_6$ alkyl group;

$R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are independently selected from H,  $C_1$ - $C_6$ alkyl, F, Cl, Br, I, OH,  $-(CH_2)_nO(C_1$ - $C_6$ alkyl),  $-(CH_2)_nO-C(=O)-(C_1$ - $C_6$ alkyl) or  $-(CH_2)_nC(=O)-O-(C_1$ - $C_6$ alkyl);

$R^9$  and  $R^{10}$  are independently H,  $C_1$ - $C_6$ alkyl or together form a  $-(CH_2)_m-$  group to produce a 5-7 membered ring;

N is from 0 to 5;

M is from 0 to 3;

and  $A^-$  is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

2 - 3. (Canceled)

4. (Currently Amended) A method of claim 1, ~~wherein the CNS disorder is a~~ for treating bipolar disorder.

5 - 9. (Canceled) A method of claim 1, wherein the CNS disorder is an anxiety disorder.

10. (Currently Amended) A method of claim 1, for treating a working memory deficit wherein the ~~CNS disorder is associated with enhanced PKC activity.~~

11. (Canceled)

12. (Original) A method of claim 1, wherein the pharmaceutical composition is administered orally and the subject is a human.


13. (Canceled)

14. (Original) A method of claim 10, wherein the pharmaceutical composition is administered orally and the subject is a human.

15.-17. (Canceled)

18. (Currently Amended) A method of treatment comprising administering to a subject suffering from manic episodes associated with enhanced PKC activity a therapeutically effective amount of chelerythrine or a pharmaceutically acceptable salt, solvate or polymorph thereof.

a composition containing a compound of the formula of the structure:



wherein:

$R^1$  and  $R^2$  are independently selected from H,  $C_1$ - $C_3$ alkyl, F, Cl, Br, I, OH,  $O(C_1$ - $C_6$ alkyl),  $O-C(=O)-(C_1$ - $C_6$ )alkyl or  $C(=O)-O-(C_1$ - $C_6$ )alkyl;

$R^3$  is H or a  $C_1$ - $C_6$ alkyl group;

$R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are independently selected from H,  $C_1$ - $C_6$ alkyl, F, Cl, Br, I, OH,  $-(CH_2)_nO(C_1$ - $C_6$ alkyl),  $-(CH_2)_nO-C(=O)-(C_1$ - $C_6$ )alkyl or  $-(CH_2)_nC(=O)-O-(C_1$ - $C_6$ )alkyl;

$R^9$  and  $R^{10}$  are independently H,  $C_1$ - $C_6$ alkyl or together form a  $-(CH_2)_m$ -group to produce a 5-7 membered ring;

N is from 0 to 5;

M is from 0 to 3;

and  $A^-$  is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

19. (Original) A method of claim 18, wherein the manic episodes are also stress induced.

20. (Previously Presented) A method for preventing manic episodes in a bipolar patient comprising administering to the subject a therapeutically effective amount of a chelerythrine.

21. (Canceled)